Clinical Trials
14 trialsNCT04550442 2026-06-05
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01333046 2026-06-03
TACTAL
Baylor College of Medicine
Phase 1 Active not recruiting
NCT07548710 2026-06-03
Study of SA+X in the Treatment of Newly Diagnosed AML
Ruijin Hospital
Phase 2 Recruiting
NCT04803201 2026-06-02
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Suspended
NCT07471841 2026-06-01
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Hoosier Cancer Research Network
Phase 2 Not yet recruiting
NCT06370000 2026-05-29
REMAIN1
Virginia Commonwealth University
Phase 4 Recruiting
NCT06445907 2026-05-29
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07404332 2026-05-28
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
University of Iowa
Phase 1 Recruiting
NCT07605949 2026-05-27
RAVEN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT06763341 2026-05-22
A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Recruiting
NCT03613532 2026-05-20
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05183035 2026-05-19
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
PedAL BCU, LLC
Phase 3 Recruiting
NCT04187703 2026-05-18
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05355051 2026-05-18
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting